Febuxostat for Treatment of Chronic Gout

Charnelda L. Gray, Pharm.D., BCPS; Nafesa E. Walters-Smith, Pharm.D., BCPS


Am J Health Syst Pharm. 2011;68(5):389-398. 

In This Article

Clinical Efficacy

The therapeutic goals of uric-acid-lowering therapy are to prevent crystal formation and to promote crystal dissolution by maintaining the serum uric acid at ≤6 mg/dL or less, which is below the saturation point for monosodium urate monohydrate.[34] The ability of febuxostat to decrease serum uric acid production through selective inhibition of enzyme xanthine oxidase has been established in short-term Phase II and III clinical trials and long-term open-label studies.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: